In addition, it was suggested that rosiglitazone may be associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance [ 38 ].
← all excerpts
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.
1
—
—